Results 211 to 220 of about 561,224 (341)

The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete withdrawal of oral glucocorticoids (OGCs).
Parameswaran K. Nair   +14 more
wiley   +1 more source

Reflections in focus: a qualitative Photovoice-informed study on pediatric patient and caregiver hospital experiences. [PDF]

open access: yesBMC Pediatr
Ekman FK   +11 more
europepmc   +1 more source

Caregiving experiences of informal caregivers

open access: yes, 2018
Met de vergrijzing en de veranderingen in de langdurige zorg neemt het belang van mantelzorg toe. Met de toenemende druk op mantelzorgers is inzicht noodzakelijk in zowel de omstandigheden waarin het verlenen van mantelzorg als belastend of negatief wordt ervaren, als in de omstandigheden waarin mantelzorgers juist positieve mantelzorgervaringen hebben,
openaire   +1 more source

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Juvenile idiopathic arthritis (JIA) is associated with impaired overall health‐related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient‐reported outcomes (PROs) in patients with JIA. Methods This was a post hoc analysis of a phase 3, randomized, double‐blind, placebo‐controlled withdrawal trial (NCT02592434) in ...
Hermine I. Brunner   +21 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi   +12 more
wiley   +1 more source

Family Decision to Immunize Against Respiratory Syncytial Virus and Associations with Seasonal Influenza and COVID-19 Vaccination. [PDF]

open access: yesVaccines (Basel)
Kaye LD   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy